• news.cision.com/
  • Follicum/
  • Follicum featured in the June issue of The New Yorker: “Is the Age-Old Quest for a Baldness Cure Reaching Its End?”

Follicum featured in the June issue of The New Yorker: “Is the Age-Old Quest for a Baldness Cure Reaching Its End?”

Report this content

Amos Barshad writes about baldness and the development of tentative cures and Follicum is among the companies mentioned in the article.

“In Sweden, a company called Follicum is now doing Phase IIA clinical studies and planning to communicate results by the end of the year. The end product will be a cream or a lotion, one that could be applied as few as three times a week. In the first trial, Follicum claims, more than seventy-five per cent of patients experienced hair growth. This is the real dream, the one so artfully captured in the Hims ads: pop a pill, slap on some cream, and get Hair God locks.”

Read the article 

For further information, please contact:
Jan Alenfall – CEO, Follicum AB

Telephone: +46 46 19 21 97
Email: info@follicum.com

About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight  since 2014. www.follicum.com

Tags:

Subscribe

Documents & Links